Relief of two built-in autoinhibitory mechanisms in P-TEFb is required for assembly of a multicomponent transcription elongation complex at the human immunodeficiency virus type 1 promoter

Molecular and Cellular Biology

Volumn 20, Issue 16, 2000, Pages 5897-5907

  Fong, Y W ^a   Zhou, Q ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR; TRANSACTIVATOR PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; RNA TRANSLATION; VIRUS TRANSCRIPTION;

CYCLIN-DEPENDENT KINASE 9; CYCLIN-DEPENDENT KINASES; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAT; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; PHOSPHORYLATION; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; PROMOTER REGIONS (GENETICS); PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033867973     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.20.16.5897-5907.2000     Document Type: Article

References (45)

1. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat
2. Specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription
3. Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1
4. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme
5. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxyterminal domain of RNA polymerase II
6. Reversible phosphorylation of the C-terminal domain of RNA polymerase II
7. Amino-terminal amino acids modulate sigma-factor DNA-binding activity
8. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
9. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T
10. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein
11. Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription
12. Upregulation of cyclin T1/CDK9 complexes during T cell activation
13. PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo
14. Autoinhibition as a transcriptional regulatory mechanism
15. Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines
16. Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation
17. Multifaceted activities of the HIV-1 transactivator of transcription, Tat
18. Taking a new TAK on tat transactivation
19. HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors
20. Tat-SF1 protein associates with RAP30 and human SPT5 proteins
21. The yeast TAF145 inhibitory domain and TFIIA competitively bind to TATA-binding protein
22. Interaction between the N-terminal domain of the 230-kDa subunit and the TATA box-binding subunit of TFIID negatively regulates TATA-box binding
23. The HIV-1 Tat cellular coactivator Tat-SF1 is a general transcription elongation factor
24. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro
25. HIV-1 Tat protein promotes formation of more-processive elongation complexes
26. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase
27. Purification of P-TEFb, a transcription factor required for the transition into productive elongation
28. SNAP(c): A core promoter factor with a built-in DNA-binding damper that is deactivated by the Oct-1 POU domain
29. Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II
30. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated Tat stimulation of HIV-1 transcription
31. A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription
32. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain
33. Identification of a cyclin subunit required for the function of Drosophila P-TEFb
34. Identification of multiple cyclin subunits of human P-TEFb
35. DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs
36. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro
37. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA
38. Role of the human homolog of the yeast transcription factor SPT5 in HIV-1 Tat-activation
39. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation
40. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines
41. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function
42. Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages
43. Novel mechanism and factor for regulation by HIV.1 Tat
44. Tat-SFI: Ofactor for stimulation of transcriptional elongation by HIV-1 Tat
45. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro